EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enantiomeric Excess Bupivacaine in a Lavender Oil NLC Tested in a Melanoma Model: Prolonged Release and Anticancer Effect

Gabriela Geronimo, Gustavo H Rodrigues da Silva iD, Ludmilla D de Moura, Fabíola V de Carvalho, Talita C Mendonça, Laura B Olivo, Bibiana Verlindo de Araújo, Teresa C Dalla Costa, Luccas Lavareze, Fernanda V Mariano, Eneida de Paula iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Gabriela Geronimo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas─UNICAMP, Campinas, SP 13083-862, Brazil. Hauptthemen laut MEDLINE: Oils, Volatile, Plant Oils, Bupivacaine, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funda??o de Amparo ? Pesquisa do Estado do Rio Grande do Sul, Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo, Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies have highlighted the potential of local anesthetics (LA) as adjuvants in cancer treatment, specifically by increasing survival rates when used in surgical excisions. However, the clinical use of LA is restricted due to their systemic toxicity. The development of drug delivery systems could address this issue and advance the utilization of these molecules. In this research, we explored the pharmacokinetics (using microdialysis probes) and antitumor properties of a nanostructured lipid carrier (NLC) formulation containing the commercially available enantiomeric excess form of bupivacaine (BVCS75). This NLC was prepared with lavender oil (NLC-L-BVC), an excipient with inherent antitumor properties. We compared this formulation to a control (NLC-BVC) using synthetic lipids. Pharmacokinetic assessments of the NLCs confirmed the sustained release of BVCS75 within the tumor, characterized by a reduced elimination rate constant and longer half-life (∼6×). The encapsulation of BVCS75 within nanoparticles (whether natural or synthetic) enhanced its effectiveness in treating the primary tumor, resulting in the inhibition of tumor growth (70% with NLC-L-BVC and 72% with NLC-BVC), outperforming free BVC (17% inhibition). However, the association of lavender oil with BVCS75 in an NLC did not yield synergistic properties. Furthermore, all BVCS75 treatments (whether free or encapsulated) improved animal survival rates. These findings confirm that encapsulation of bupivacaine in NLC can prolong drug action at the local site, contributing to improved local antitumor therapy while mitigating systemic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oils, VolatilePlant OilsBupivacaineAntineoplastic AgentsMelanomaAnimalsMiceLavandulaDelayed-Action PreparationsCell Line, TumorLipidsAnesthetics, LocalDrug CarriersNanoparticlesHumansFemaleMaleStereoisomerismDrug Delivery Systems

Stichwörter der Autor:innen

bupivacainedrug deliverylavender oilmelanomananostructured lipid carriers

Substanzen

lavender oilOils, VolatilePlant OilsBupivacaineDelayed-Action PreparationsLipidsAnesthetics, LocalDrug CarriersAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas─UNICAMP, Campinas, SP 13083-862, Brazil.
  • Brazilian Biosciences National Laboratory, Brazilian Center for Research in Energy and Materials, Campinas, SP 13083-970, Brazil.
  • Pharmaceutical Sciences Graduate Program, Faculty of Pharmacy, Federal University of Rio Grande do Sul─UFRGS, Porto Alegre, RS 90610-000, Brazil.
  • Department of Pathology, Faculty of Medical Sciences, UNICAMP, Campinas, SP 13083-888, Brazil.

ORCID-Profile: Gustavo H Rodrigues da Silva, Eneida de Paula

Förderung

  • Funda??o de Amparo ? Pesquisa do Estado do Rio Grande do Sul
  • Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo
  • Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior

Zitieren

APA

Geronimo, G., Rodrigues da Silva, G. H., de Moura, L. D., de Carvalho, F. V., Mendonça, T. C., Olivo, L. B., Verlindo de Araújo, B., Dalla Costa, T. C., Lavareze, L., Mariano, F. V., & de Paula, E. (2025). Enantiomeric Excess Bupivacaine in a Lavender Oil NLC Tested in a Melanoma Model: Prolonged Release and Anticancer Effect. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00254

Vancouver

Geronimo G, Rodrigues da Silva GH, de Moura LD, de Carvalho FV, Mendonça TC, Olivo LB, et al. Enantiomeric Excess Bupivacaine in a Lavender Oil NLC Tested in a Melanoma Model: Prolonged Release and Anticancer Effect. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00254

BibTeX
@article{Geronimo2025,
  author = {Geronimo, Gabriela and Rodrigues da Silva, Gustavo H and de Moura, Ludmilla D and de Carvalho, Fabíola V and Mendonça, Talita C and Olivo, Laura B and Verlindo de Araújo, Bibiana and Dalla Costa, Teresa C and Lavareze, Luccas and Mariano, Fernanda V and de Paula, Eneida},
  title = {Enantiomeric Excess Bupivacaine in a Lavender Oil NLC Tested in a Melanoma Model: Prolonged Release and Anticancer Effect},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00254}
}
Kostenlos starten →